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Background: Agents currently used for the treatment and prevention of thrombosis have a
number of side effects. We conducted this study to develop antithrombotic agents from
herbs that are used in food.
Methods: The 80% (v/v) ethanol extracts of Phyllostachys pubescens leaf (PL) andMume Fructus
(MF) and their combinations—2:1 (PM21), 1:1 (PM11), and 1:2 (PM12)—were evaluated on rat
platelet aggregation induced by adenosine diphosphate (ADP) in vitro and on arteriovenous
shunt thrombosis after 3 days of oral treatment in rats in vivo.
Results: At 100g/mL, PM21 and PM11 inhibited in vitro ADP-induced aggregation by
44.0±4.3% and 30.0±3.2%, respectively, whereas PL, MF, and PM12weakly or scarcely inhib-
ited ADP-induced aggregation by 3.9±3.2%, 13.0±2.7%, and 5.2±1.3%, respectively. The
IC50 values of PM21 on ADP-, collagen-, and thrombin-induced platelet aggregations were
135.6±7.4g/mL, 142.7±5.8g/mL, and 186.5±9.7g/mL, respectively. In an in vivo rat
arteriovenous-shunt thrombosis model, thrombus weight was signiﬁcantly decreased after
the oral administration of 400mg/kg PL (27.8±3.0%, p<0.01) or MF (35.2±2.1%, p<0.01),
and with a good accord to the in vitro results, the combination of PL and MF in the ratio of
2:1, PM21 (60.9±1.2%, p<0.001), showed a superior antithrombotic effect to those of indi-
vidual extracts. At dosages of 200mg/kg, 100mg/kg, and 50mg/kg, PM21 dose-dependently
decreased thrombosis weight (ED50, 314mg/kg).
Conclusion: These results suggest that combination preparations of PL and MF, especiallytheir 2:1 combination, can increase antiplatelet and antithromboticeffects more than PLand MF alone, offering ev
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∗ Corresponding author. Basic Herbal Medicine Research Group, Kore
E-mail address: dskim@kiom.re.kr (D.-S. Kim).
http://dx.doi.org/10.1016/j.imr.2013.04.005
2213-4220/© 2013 Korea Institute of Oriental Medicine. Published by Else
(http://creativecommons.org/licenses/by-nc-nd/4.0/).idence for a potential novel combination antithrombotic therapy.
f Oriental Medicine. Published by Elsevier. This is an open access
article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
a Institute of Oriental Medicine, Daejeon 305-811, South Korea
vier. This is an open access article under the CC BY-NC-ND license
W scens
1
P
o
V
a
e
c
e
c
a
b
a
e
a
t
o
a
a
i
m
h
E
f
a
i
f
a
d
a
w
s
a
a
ﬂ
h
r
i
a
b
b
t
l
t
(
2
2
p
P
J
H
m.Y. Jin et al/Antiplatelet and antithrombotic effect of Phyllostachys pube
. Introduction
latelet aggregation is a physiological mechanism that seals
ff the damaged blood vessel wall to prevent blood loss.
arious endogenous factors such as collagen, thrombin,
denosine diphosphate (ADP), serotonin, vasopressin, and
pinephrine induce platelet activation followed by shape
hange and aggregation. Under pathological conditions, how-
ver, platelets also play a key role in the pathogenesis of
oronary cardiovascular diseases, including artery disease and
rthrosclerosis. Most acute coronary syndromes are caused
y platelet adhesion, aggregation, and thrombus formation in
reas of ruptured atheromatous plaques.1,2 Since the discov-
ry of acetylsalicylic acid, heparin, and warfarin, the use of
ntiplatelet and anticoagulation agents in the prevention and
reatment of cardiac disease, especially during early treatment
f acute myocardial infarction, has become widespread. The
ntiplatelet and antithrombotic agents of many plants such
s Veratrum patulum,3 sesame seed,4 Magnolia obovata,5 Angel-
ca sinensis,6 Ginkgo biloba,7 olive oil,8 Korean red ginseng,9
ulberries,10 Common thyme and rosemary,11 Lavandula
ybrida,12 onion,13 Glycyrrhiza glabra,14 Gardenia jasminoides,15
vodia rutaecarpa,16 and garlic,17 have been investigated.
Phyllostachys pubescens, which belongs to the Gramineae
amily, is an important bamboo species in Korea, Japan,
nd China. It has been commonly used throughout history
n Chinese medicine for treating infections and for many
orms of healing. Recently, it has been reported to contain
gents of many kinds of biological activities, such as antioxi-
ant activity,18 antiobesity activity,19 antitumor activity,20 and
ntimicrobial activity.21
Mume Fructus (MF) is produced by baking unripe fruits,
hich are gathered at the beginning of summer, until their
kins turn black. It has been used in Chinese medicine to
stringe the lungs and stop coughing, to restrain the intestines
nd stopdiarrhea, aswell as topromote theproductionof body
uids, and to expel roundworms. It has been reported that MF
as antimicrobial activity,22 hypouricemic effect,23 antibacte-
ial effect,24 antioxidant activity,25 antitumor activity,26 and
mmune-enhancing effect,27 etc.
The anticoagulant activity,28 antiplatelet aggregation, and
ntithrombotic activity29 of P. pubescens leaves have similarly
een reported; however, their combined preparation has not
een investigated until now. The aim of the present study was
o investigate the ethanol extracts of Phyllostachys pubescens
eaf (PL) and Mume Fructus (MF), and their combined prepara-
ions, on platelet aggregation in vitro and on rat arteriovenous
AV) shunt thrombosis in vivo.
. Methods
.1. Preparation of the ethanol extracts from the
lants and their combinations. pubescens leaf was collected from Damyang, Korea, on
uly 27, 2012, and MF was purchased from the Bakjedang
erbal Medicine Shop in Daejeon, Korea. The voucher speci-
ens were identiﬁed in the Basic Herbal Medicine Research71
Group at the Korea Institute of Oriental Medicine. Authen-
ticated voucher specimens (BL-20120727; MF-20120725) were
deposited in the Herbarium of the Korea Institute of Oriental
Medicine.
The pulverized P. pubescens leaves (100 g) and MF (100 g)
were each soaked in 1 Lof 80% (v/v) ethanol inwater for 5hours
under mantle reﬂux. The extracts were ﬁltered and then were
evaporated under reduced pressure in a rotary evaporator (N-
1000 S; EYELA, Tokyo, Japan) to obtain P. pubescens leaf extract
(PL, 8.7 g) and MF extract (18.9 g). Three combinations of these
extractswere prepared as follows: PM21, PM11, and PM12were
formulated by mixing PL and MF at a ratio of 2:1, 1:1, and 1:2,
respectively.
2.2. High-performance liquid chromatography
analysis of marker compounds
High-performance liquid chromatography (HPLC)-grade
reagents, acetonitrile, and water were obtained from J. T.
Baker (Phillipsburg, NJ, USA). All other chemicals were of
reagent grade.
The sample was analyzed by reverse-phase HPLC using
Waters Alliance 2695 system (Waters Co., Milford, MA, USA),
coupled with a 2996 photodiode array detector. Phenomenex
Luna C18 column (250×4.6mm; particle size 5m; Phe-
nomenex, Torrance, CA, USA) was used as the stationary
phase, and themobile phasewas composed of 0.1% (v/v) triﬂu-
oroacetic aqueous solution (A) and acetonitrile (B). The elution
conditions were as follows: at t=0minute, the mobile phase
consisted of 90% A/10% B and was held for 10minutes. From
10minutes to 30minutes, a gradientwas applied to 70%A/30%
B,whichwas followed by awashwith 100%B for 5minutes and
a 15-minute equilibration period at 90% A/10% B. The separa-
tion temperature was kept at a constant 40 ◦C throughout the
analysis, with a ﬂow rate of 1.0mL/min and injection volume
of 20L.
Identiﬁcation was based on retention time and UV spec-
tra by comparison with commercial standards. For each
compound, peak areas were determined at the wavelength
providing maximal UV absorbance. Calibration curves of the
standards ranging from 1.25g/mL to 40g/mL (6 levels) for
5-hydroxymethylfurfural and from 12.5g/mL to 400g/mL (6
levels) for isoorientin revealed good linearity, with R2 values
exceeding 0.99 (peak areas vs. concentration).
Quantitation was performed on the basis of external stan-
dards with a mixture of standards of known concentration
that were analyzed in duplicate prior to and after the batch of
samples, and the peak areaswere used to calculate the sample
contents of the compounds.
2.3. Preparations of platelet-rich plasma and platelet
aggregation assay
Sampleswere prepared according to standard practice30–33: SD
rat blood (10mL) was obtained by cardiac puncture (by insert-
ing a 23-gauge needle into the cardiac puncture), and samples
were transferred to a 15-mL test tube containing 1mL citrate
phosphate dextrose solution (CPD: 90mM Na3 C6H5O7·2H2O,
14mMC6H8O7·H2O, 128.7mMNaH2PO4·H2O,and 2.55 g/100mL
dextrose).
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Platelet-rich plasma (PRP) was obtained after blood sample
centrifugation at 170× g for 5minutes. The PRP samples were
again centrifuged at 120×g for 5minutes to remove residual
erythrocytes. In order to remove the CPD solution and to iso-
late the platelets, the PRP was centrifuged twice at 350× g
for 10minutes, and the supernatant was then isolated as a
platelet-poor plasma fraction, which was used as a reference
solution in aggregation assays. The platelets of the precipitate
were adjusted to the proper number (108/mL) for the aggre-
gation assay in Tyrode buffer (137mM NaCl, 12mM NaHCO3,
5.5mM glucose, 2mM KCl, 1mM MgCl2, 0.3mM NaHPO4, and
pH=7.4). All platelet preparations were conducted at room
temperature.
Samples and aspirin were dissolved in a 50% DMSO solu-
tion to obtain primary solutions of 0.2 g/L. These were then
serially diluted with saline solution to obtain the required
concentrations. The control was a saline solution with 0.5%
DMSO solution. ADP, collagen, and thrombin (Sigma-Aldrich,
St. Louis, MO, USA) were used to induce platelet aggregation.
Aggregation was monitored by measuring light transmission
via a platelet aggregometer (Chrono-Log corporation, Haver-
town, PA, USA). The washed platelets were preincubated at
37 ◦C for 5minutes with either samples or vehicle, and then
ADP (10M), collagen (5g/mL), or thrombin (0.5 unit/mL) was
added. The aggregation curves were recorded for 6minutes.
Maximum aggregation was recorded for the control (CA) and
for the tests (TA). The inhibition of aggregation (IA) was calcu-
lated as: IA= (CA – TA/CA)×100.
2.4. In vivo experiments
2.4.1. Animals
Male Sprague–Dawley ratsweighing 300–350 gwere purchased
from Japan SLC (Hamamatsu, Japan). They were kept in a
temperature-controlled environment (20 ◦C)with a 12:12-hour
light–dark cycle, and were fed with standard chow for at least
1 week prior to the initiation of any testing. Our study was
approved by the committee for animal welfare at Daejeon
University. Moreover, all animal procedures were conducted
in accordance with the guidelines of the Institutional Animal
Care and Use Committee of the Korea Research Institute of
Bioscience and Biotechnology (Daejeon, South Korea).
2.4.2. Treatments
Rats were orally administered (by gavage) with 400mg/kg,
200mg/kg, 100mg/kg, and 50mg/kg crude extract dissolved
in 0.25% carboxymethylcellulose solution (Sigma) at the same
time of the day for 3 consecutive days. The shunt thrombo-
sis model was tested 2hours after the last administration. Six
rats were used for each test.
2.4.3. In vivo effect on a rat model of AV shunt thrombosis
The model tested was a rat AV shunt thrombosis model.34
After anesthesia with urethane (1.25 g/kg, i.p.; Sigma), an
8-cm polyethylene tube was inserted between the left jugu-
lar vein and the right carotid artery. The saline-ﬁlled shunt
was assembled by connecting two cannulae with slightly
curved 6-cm-long tygon tubing (internal diameter, 2mm) con-
taining a 5-cm-long cotton thread (diameter, 0.25mm) that
had been scraped with a scalpel blade to make it moreIntegr Med Res ( 2 0 1 3 ) 70–75
thrombogenic. Extracorporeal circulation was maintained for
15minutes, during which time a thrombus adhered to the cot-
ton thread. The shunt was then removed and the thread, with
its associated thrombus,waswithdrawnandwas immediately
weighed. The thrombus wet weight was then determined by
subtracting the weight of the dry 5 cm cotton thread.
2.5. Statistical analysis
Differences between treatment groups were examined using
an unpaired Student t test. All data are presented as
means± standard deviation (SD). Differences between groups
were considered signiﬁcant when p<0.05.
3. Results
3.1. Chromatographic separation of PM21
Two marker compounds were determined from major
peaks by comparison of retention time and UV spectra
on HPLC/PDA chromatogram with commercial standards.
As shown in Fig. 1, PLC analysis of PM21 revealed two
standards—5-hydroxymethylfurfural and isoorientin—at a
retention time of approximately 5.8minutes and 21.5minutes.
PM21 contained 0.08±0.01mg/g for 5-hydroxymethylfurfural
and 4.8±0.07mg/g for isoorientin.
3.2. In vitro effect on agonist-induced rat platelet
aggregation
The 80% (v/v) ethanol extracts of PL and MF and their com-
binational preparations of 2:1 (PM21), 1:1 (PM11), and 1:2
(PM12) on ADP-induced platelet aggregation in vitro were
evaluated using washed rat platelets. At the concentration
of 100g/mL, PM21 and PM11 inhibited platelet aggrega-
tion by 44.0±4.3% and 30.0±3.2%, respectively, whereas PL,
MF, and PM12 weakly or scarcely inhibited platelet aggre-
gation by 3.9±3.2%, 13.0±2.7%, and 5.2±1.3%, respectively,
compared to control (Fig. 2). PM21 (p<0.001, to both) and
PM11 (p<0.001 and p<0.05, respectively) also showed a sig-
niﬁcant difference from PL or MF. We further determined
the half-maximal inhibitory concentration (IC50) of PM21
on collagen- and thrombin-induced platelet aggregations as
well as ADP-induced platelet aggregation. The IC50 values
of PM21 on ADP-, collagen-, and thrombin-induced platelet
aggregations were 135.6±7.4g/mL, 142.7±5.8g/mL, and
186.5±9.7g/mL, respectively.
3.3. In vivo effect on a rat model of AV shunt
thrombosis
The AV shunt thrombosis model has been commonly used
to assess antithrombotic effects.34 As shown in Fig. 3, after
the oral administration of 400mg/kg of PL or MF, thrombus
weight was signiﬁcantly decreased by 27.8±3.0% (p<0.01)
and 35.2±2.1%, (p<0.01), respectively, and in good agree-
ment with in vitro results, the combination of PL and MF
in the ratio of 2:1 (PM21; 60.9±1.2%, p<0.001) showed a
superior antithrombotic effect compared with that observed
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Fig. 1 – HPLC chromatogram of (A) two standards mixture and (B) the 80% (v/v) ethanol extracts combinational preparation
PM21 at 280nm. 5-Hydroxymethylfurfural (1) and isoorientin (2) appeared at a retention time of approximately 5.8minutes
and 21.5minutes, respectively. PM21 contained 0.08±0.01mg/g for 5-hydroxymethylfurfural and 4.8±0.07mg/g for
isoorientin. HPLC, high-performance liquid chromatography.
Fig. 2 – Effect of Phyllostachys pubescens leaf extract (PL),
Mume Fructus extract (MF), and the 2:1, 1:1, and 1:1
combinations (PM21, PM11, and PM21, respectively) from
these two extracts on adenosine diphosphate
(ADP)-induced rat platelet aggregation in vitro. The washed
platelets from SD rats were pre-incubated at 37 ◦C for
5minutes with either samples (100g/mL) or vehicle, and
then ADP (10M) was added. The aggregation curves were
recorded for 6minutes. Maximum aggregation was
recorded for the control (CA) and for the tests (TA). The
inhibition of aggregation (IA) was calculated as: IA= (CA –
TA/CA)×100. Data are presented as mean±SD. *p<0.05,
†p<0.01.
Fig. 3 – Effect of Phyllostachys pubescens leaf extract (PL),
Mume Fructus extract (MF), and their 2:1 combination
(PM21) of these two extracts on AV shunt thrombosis.
Rivaroxaban (Riv) was used as a positive control. After
anesthesia with urethane, an 8-cm polyethylene tube was
inserted between the left jugular vein and the right carotid
artery of SD rats. The saline-ﬁlled shunt was assembled by
connecting two cannulae with slightly curved tubing
containing a cotton thread that had been scraped with a
scalpel blade to make it more thrombogenic. Extracorporeal
circulation was maintained for 15minutes, during which
time a thrombus adhered to the cotton thread. The
thrombus wet weight was then determined by subtracting
the weight of the dry cotton thread. Data are shown as
mean±SD. *p<0.01, †p<0.001 versus vehicle control.
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for each extract. PM21 also achieved statistical signiﬁcance,
with p=0.00047 compared to PL and p=0.00052 compared
to MF. At the additional dosages of 200mg/kg, 100mg/kg,
and 50mg/kg, PM21 dose-dependently decreased the throm-
bosis weight by 35.2±5.4% (p<0.01), 29.8±1.9% (p<0.01),
and 12.2±3.6%, respectively, compared to the vehicle control
(ED50, 314mg/kg).
4. Discussion
Arterial thrombi are well known to be largely composed of
aggregated platelets. Platelets play a vital role in both the ini-
tiation and growth of thrombi. Thus, the inhibition of platelet
function represents a promising approach for the preven-
tion of thrombotic disorder. In the present study, PL and MF,
which are used in Oriental herbal medicine, and their combi-
nation preparations (PM21, PM11, and PM12) were evaluated
in vitro for their antiplatelet aggregation activity induced by
ADP in vitro. MF showed weak inhibition, and PL showed
scarcely any inhibition at 100g/mL. By contrast, PM21 and
PM11 showed signiﬁcantly higher inhibition compared to PL
or MF alone. Park et al29 reported that MF weakly inhibited
platelet aggregation, even at a high concentration of 1mg/mL.
The antiplatelet aggregation effect of PL was not previously
reported, but the anticoagulant activity, as an intrinsic path-
way of activated partial thromboplastin time, had previously
been shown to be weak, even at a high concentration of
1.2mg/mL.28 This study suggests that the antiplatelet effect
of PL or MF alone can be signiﬁcantly increased by their com-
bination.
Antithrombotic therapy has proven to be effective for
the treatment of cardiovascular diseases. In the current
study, PM21, which showed superior in vitro antiplatelet
effects among the three combinations, was evaluated for
its antithrombotic effect using the rat AV shunt throm-
bosis model in vivo, and in comparison with PL and MF
used alone. PM21 showed a signiﬁcantly (p<0.001) higher
antithrombotic effect compared to PL or MF alone. Consid-
ering the traditional applications of PL and MF in Oriental
medicine, which have mostly been used to nourish the
blood and improve blood circulation for the treatment of
cardiovascular diseases, the antithrombotic effect of PM21
demonstrated in the present study might provide new
evidence for the greater beneﬁt of using this combined
approach.
In conclusion, our results suggest that combined prepara-
tions of PL and MF, especially at a ratio of 2:1, can increase
their antiplatelet and antithrombotic effects thanwhen either
agent is used alone, offering experimental evidence for a
potential novel combination antithrombotic therapy. Further
studies will be conducted to optimize the combination ratio
of PL and MF and to investigate their synergistic mecha-
nism.Conﬂict of interest
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